Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AV-GBM-1 + granulocyte-macrophage colony stimulating factor
- Development stage
- Unknown
- Lead developer
- Aivita Biomedical
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
AV-GBM-1 + granulocyte-macrophage colony stimulating factor is a personalized autologous dendritic cell vaccine combination developed by Aivita Biomedical for the treatment of newly diagnosed glioblastoma. The vaccine component, AV-GBM-1, is produced by loading a patient's own dendritic cells with a lysate of irradiated autologous tumor-initiating cells (TICs) harvested from the patient's tumor. This approach is designed to target the self-renewing cells responsible for tumor growth and recurrence. The vaccine is administered subcutaneously alongside 500 μg of granulocyte-macrophage colony stimulating factor (GM-CSF), which functions as an immune adjuvant to enhance the presentation of tumor antigens and boost the overall anti-tumor immune response. A Phase II clinical trial has evaluated its safety and efficacy in patients with newly diagnosed glioblastoma.
- Other names
- AV-GBM-1 + GM-CSFAivita glioblastoma vaccine
Beyond the preview
Go deeper on AV-GBM-1 + granulocyte-macrophage colony stimulating factor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AV-GBM-1 + granulocyte-macrophage colony stimulating factor.